ReviewDiscover nano2025
Nanomedicine approaches to enhance the effectiveness of meropenem: a strategy to tackle antimicrobial resistance.
Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Glucosamine functionalized multi-walled carbon nanotubes as potential antibacterial molecules.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- Assessment of MgO, ZnO, chitosan hydroxyapatite and silver hydroxyapatite nanoparticles against carbapenem-resistant Gram-negative Egyptian clinical isolates: a combined in-silico and in-vitro study.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meropenem, a carbapenem typically reserved for treating severe infections, has encountered resistance from certain bacteria, including multidrug-resistant (MDR) strains of Pseudomonas aeruginosa (P. aeruginosa) and Klebsiella pneumonia (K. pneumonia). Nanoparticles (NPs) have emerged as a promising strategy to combat drug-resistant bacteria. By targeting specific biosynthetic and enzymatic pathways and penetrating bacterial membranes, NPs can function as antibiotic delivery systems (nanocarriers) or exhibit intrinsic antibacterial properties. When combined with various types of nanoparticles-such as lipid- and polymer-based NPs, metallic NPs, silica NPs, nanoemulsions, niosomes, carbon NPs, and nanocomposites-meropenem has shown enhanced effectiveness in overcoming resistance to MDR bacteria and reducing adverse effects. However, several challenges persist, including scaling up industrial production, ensuring safety and favorable toxicity profiles, and addressing the limited availability of in vivo evidence. This review explores nanoparticle strategies to combat resistance to meropenem.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.